How safe is stem cell therapy for kidney disease?

Large safety analyses across many conditions show that the most consistent side effect of IV MSCs is a temporary fever, without increased rates of infection, blood clots, cancer or death in controlled trials. However, people with kidney disease have particular vulnerabilities, including fluid and electrolyte balance, blood pressure, anemia, a tendency to blood clotting in some kidney conditions and, for some, dialysis schedules or transplant medications, that require careful screening and monitoring. Stem cell therapy is not a cure for kidney disease; its goal is to support the body's repair mechanisms and quality of life alongside nephrology care. At Stem Cell Mexico, kidney protocols use allogeneic MSCs derived from umbilical cord tissue, given by slow IV infusion with medical observation, and always as a complement to nephrology care.

This guide explains what is known about safety in kidney disease, which factors increase risk and how risks are minimized.

What the evidence shows

Safety of IV MSCs in general

• A systematic review in EClinicalMedicine (Thompson and colleagues, 2020) of 55 randomized trials with 2,696 patients found that intravascular MSCs were associated with temporary fever, but not with increased acute infusion toxicity, infections, thrombotic events, malignancy or death.
• A 2026 analysis focused on umbilical cord MSCs, published in Stem Cells Translational Medicine (Hum and colleagues), included 42 randomized trials with 2,280 patients and found similar results: more temporary fever, no signals of harm for other serious events, and a recommendation for continued long-term monitoring.

Kidney-specific research

A 2025 systematic review and meta-analysis in Cells (Pura and colleagues) evaluated MSCs in CKD, including three randomized trials with 86 participants. No specific safety concerns were highlighted. In human trials, protein in the urine decreased, a marker linked to slower kidney disease progression.

What this means

The cell type has a reassuring safety record, and kidney trials so far have not raised specific safety concerns. Careful individual evaluation is essential, and benefit should not be overstated.

Understanding fever after an infusion in kidney disease

Temporary fever is the most consistently reported side effect of IV MSCs. It usually appears within hours and resolves within one to two days, reflecting a brief immune response rather than infection. In kidney patients, fever and the sweating or reduced fluid intake that can accompany it may affect fluid balance and blood pressure, so temperature is monitored during observation and paracetamol is generally used if needed. Anti-inflammatory painkillers are avoided, both because they can harm the kidneys and because they may interfere with the cells. A high, persistent or worsening fever, or fever with painful urination or back pain, should be evaluated promptly, as it may indicate an infection unrelated to the cells.

Why kidney patients need extra care

Fluid balance

Reduced kidney function makes it harder to eliminate extra fluid. Infusion volumes and any IV fluids are kept as low as appropriate and given slowly, especially in patients with heart disease or swelling.

Electrolytes and acid-base balance

Potassium, sodium and bicarbonate levels can be abnormal in CKD. Pre-treatment blood tests check these values, and treatment is postponed if they are unsafe.

Blood pressure

Many kidney patients have high blood pressure and take several medications. Fasting, travel and infusion reactions can cause swings in blood pressure, which are monitored.

Anemia

Anemia is common in CKD and can worsen fatigue. Hemoglobin is checked before treatment.

Clotting tendency

Some kidney conditions, such as nephrotic syndrome, increase the risk of blood clots. Thrombotic events have not been increased with MSCs in trials, but individual clotting risk is reviewed carefully.

Medications cleared by the kidneys

Sedatives, pain medications and other drugs may need dose adjustment in reduced kidney function. Paracetamol is generally preferred over anti-inflammatory painkillers, which can harm the kidneys and are avoided around cell treatment anyway.

Dialysis

For patients on dialysis, treatment is scheduled in coordination with dialysis sessions to avoid fluid overload and ensure stable electrolytes.

Kidney transplant recipients

Transplant recipients take immunosuppressive drugs and have special infection and rejection considerations. They require coordination with the transplant team and individual assessment.

Diabetes, high blood pressure and kidney safety

Because diabetes and high blood pressure are the leading causes of CKD, many patients considering treatment live with both. Blood sugar should be reasonably controlled before treatment, and the fasting period on the morning of the procedure requires a plan for insulin or oral diabetes medications to avoid low blood sugar. Some diabetes medications, such as metformin or SGLT2 inhibitors, may need temporary adjustments around procedures, which your doctor will advise. Blood pressure medications are generally continued. Good control of both conditions after treatment remains the most powerful way to protect your kidneys, regardless of any regenerative therapy.

How we reduce risk

• Review of kidney labs and nephrology notes: eGFR trends, creatinine, urine albumin-to-creatinine ratio, electrolytes, hemoglobin and medications.
• Stability requirement: no rapidly declining kidney function, recent hospitalization or uncontrolled blood pressure.
• Pre-treatment testing on arrival: complete blood count, comprehensive metabolic panel, urinalysis and tumor markers.
• Quality-controlled cells: donor screening, infectious disease testing, and laboratory quality testing before release.
• Slow infusion and monitoring of blood pressure, heart rate, oxygen levels and temperature.
• Observation with nursing and medical supervision, often overnight.
• Medication review to avoid kidney-harmful drugs and adjust doses when needed.
• Coordination with your nephrologist and clear instructions for follow-up labs.

Who should not be treated, or should wait

• Rapidly progressive kidney failure or acute kidney injury.
• Dangerous electrolyte levels or severe fluid overload.
• Uncontrolled high blood pressure or unstable heart failure.
• Active infection, including urinary tract infections.
• Cancer within the past five years.
• Situations where dialysis or transplant planning should take priority.
• Pregnancy, during which regenerative treatments are not performed.

Safety and benefit are separate questions

International guidelines, including the KDIGO 2024 Clinical Practice Guideline for CKD and patient guidance from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), emphasize proven measures that slow kidney disease: controlling blood pressure and blood sugar, using kidney-protective medications when appropriate (such as ACE inhibitors, ARBs and SGLT2 inhibitors), reducing urine protein, avoiding kidney-toxic drugs and adjusting diet. Stem cell therapy should never replace these treatments, and medications should not be stopped because of a regenerative procedure. Any potential benefit should be measured objectively with follow-up labs.

Regulatory context

No stem cell product is approved by the FDA or the European Medicines Agency for kidney disease. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS. Ask for documentation of the cells and facility.

Preparing for treatment

Bring recent lab results (eGFR, creatinine, electrolytes, urine albumin-to-creatinine ratio, hemoglobin) and a complete medication list. Continue blood pressure and other essential medications unless instructed otherwise. Follow any fluid restriction your nephrologist has set. Pause anti-inflammatory painkillers and supplements as instructed, which is also good for kidney health. If you are on dialysis, share your schedule so treatment can be coordinated.

After treatment

Expect possible mild fever or fatigue for a day or two. Repeat kidney labs at the intervals agreed with your doctors, typically one, three and six months after treatment, to monitor safety and track any changes. Keep your nephrology appointments and continue all prescribed therapies. Share your medical report and the documentation of the cells you received with your nephrologist, so they can interpret any lab changes in context and decide on next steps together with you.

Signs to report after treatment

Seek prompt care or contact the team for a significant decrease in urine output, rapid weight gain or new swelling, shortness of breath, high or persistent fever, chest pain, severe weakness or palpitations (which can signal electrolyte problems), or painful urination.

What our patients usually receive

Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:

• Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
• One night at our facilities, sometimes two, with nursing and medical monitoring.
• Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
• Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.

Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.

Questions to ask during your evaluation

• Is my kidney function stable enough for treatment now?
• How will fluids, blood pressure and electrolytes be monitored?
• Which of my medications need adjustment?
• How will you coordinate with my nephrologist or dialysis unit?
• Which lab values will we follow afterward, and when?

Bottom line

MSC therapy has a reassuring general safety profile, and small kidney trials have not raised specific concerns, but kidney patients need careful screening of fluids, electrolytes, blood pressure, clotting risk and medications. Treatment complements, not replaces, nephrology care. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your kidney condition, goals and medical history.